Dale Pfost, Ph.D.
Dale Pfost is the U.S.-based General Partner of London-based Advent Life Sciences and has 25 years of experience as a life science entrepreneur and executive. He has been the CEO of five successful biotechnology companies, three of which became publicly traded, with valuations of over $1 billion. Dale has led 20 financings raising $300 million, has led the M&A of nine companies and has served on multiple public and private company boards. He was also the founding CEO of Acuity Pharmaceuticals, which had the first-ever clinical trial with an siRNA drug and was merged to form OPKO Health. Dale was the founding CEO of both Oxford GlycoSciences and Orchid BioSciences, both of which went public. His first company was acquired by SmithKline Beckman and produced the Biomek, a leading laboratory automation system. He has a Ph.D. in Physics from Brown University and a BS in Physics from the University of California, Santa Barbara.